anistreplase

(redirected from Eminase)

anistreplase

 [an″is-trep´lās]
a thrombolytic agent primarily used to clear coronary vessel occlusions associated with myocardial infarction; administered intravenously.

anistreplase

/an·is·trep·lase/ (an″is-trep´lās) a thrombolytic agent used to clear coronary vessel occlusions associated with myocardial infarction.

anistreplase

a plasminogen activator.
indication This drug is used in acute MI for lysis of coronary artery thrombi.
contraindications Known hypersensitivity to this drug or streptokinase; active internal bleeding; intraspinal or intracranial surgery; central nervous system neoplasms; severe, uncontrolled hypertension; cerebral embolism; thrombosis; hemorrhage; recent trauma; or history of cerebrovascular accident all prohibit the use of this drug.
adverse effects Adverse effects of this drug include headache, fever, sweating, agitation, dizziness, paresthesia, tremor, vertigo, hypotension, conduction disorders, nausea, vomiting, decreased hematocrit, surface bleeding, rash, urticaria, phlebitis at the injection site, itching, flushing, low back pain, arthralgia, altered respirations, and dyspnea. Life-threatening side effects include intracranial hemorrhage, dysrhythmias, GI bleeding, genitourinary bleeding, intracranial bleeding, retroperitoneal bleeding, thrombocytopenia, bronchospasm, lung edema, and anaphylaxis.

anistreplase

See APSAC.

anistreplase

A clot-dissolving drug used to try to re-establish blood flow in the heart muscle in the early treatment of heart attacks. A brand name is Eminase.
References in periodicals archive ?
Eminase is indicated for use in the dissolution of thrombi (clots) obstructing coronary arteries, to improve ventricular function, and to reduce mortality associated with acute myocardial infarction.
Roberts acquired the worldwide rights to Eminase form SmithKline Beecham in 1995 and has since been positioning the product for international market opportunities.
The pricing decision also has left the product open to vicious competition from $1,700-a-dose Eminase, produced by SmithKline Beecham, and Astra Kabi's streptokinase, priced at $200 a dose.
After excluding sales of NOROXIN, TIGAN and EMINASE, all other pharmaceutical product sales increased approximately 45%.
Sales of Roberts core products, excluding Tigan, Eminase and Noroxin, are showing improvement over the first quarter of the current year, indicating that the Company is beginning to recover from the first quarter slump in core product sales.
products TIGAN and EMINASE from SmithKline Beecham and released a
In other news, Roberts reported that the Federal Trade Commission completed its review of Roberts previously announced plan to acquire the Tigan and Eminase prescription product lines from SmithKline Beecham.
Eminase (anistreplase) is a thrombolytic drug used in the treatment of acute heart attack to dissolve blood clots obstructing coronary arteries.
EMINASE is to be administered easily and quickly: a five-minute bolus injection versus a lengthy infusion, making EMINASE unique and ideal for pre-hospital use.
The study drug is Eminase, the genetically-engineered
SmithKline Beecham's Eminase (Anistreplase), a thrombolytic drug for treating myocardial infarction.